AMAG Escapes Suit Over Preterm Birth Drug's Effectiveness

Law360 (May 25, 2021, 5:49 PM EDT) -- A New Jersey federal judge on Tuesday threw out a suit alleging that AMAG Pharmaceuticals Inc. misleads consumers into believing one of its drugs prevents women from giving birth prematurely, saying any claims from before March 2019 are preempted.

According to the order, none of the women who are plaintiffs in the suit allege when they were administered Makena, or hydroxyprogesterone caproate, so the judge cannot determine which claims — if any — can move forward, and dismissed the complaint without prejudice.

While the women had cited in their complaint a study that showed doubt in the drug's efficacy, U.S. District...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!